The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus with the accession number of CCTCC NO: V201950. Further provided are a vaccine composition containing the F-genotype mumps virus attenuated strain as an active ingredient and a preparation method thereof.

Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.

The present invention provides constructs of the parainfluenza virus type-5 (PIV5) virus expressing the SARS-CoV-2 envelope spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 variants for use as safe, stable, efficacious, and cost-effective vaccines against COVID-19.

A composition for treating or preventing COVID-19 infection is described. The composition includes attenuated Measles virus particles; attenuated Mumps virus particles; attenuated Rubella II virus particles; scorpion antivenom; and a pharmaceutically acceptable carrier. The composition can be used in a method of treating COVID-19 infection in a subject, and can also be used in a method of vaccinating a subject to decrease the risk or severity of infection by COVID-19.

This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.

The present invention provides attenuated, aroA mutant B. bronchiseptica strains that are effective to elicit an immune response in an animal against B. bronchiseptica. Also provided are immunogenic compositions and vaccines which include the attenuated, aroA mutant B. bronchiseptica strains. Also provided are kits for use with such compositions and vaccines. Also provided are methods of orally administering attenuated, aroA mutant B. bronchiseptica strains, compositions, and vaccines to animals.

Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.

The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.

The present invention aims to provide a composition for promoting immunity induction and a vaccine pharmaceutical composition which are universally usable for inducing immunity to various antigens and capable of exerting a high immunity inducing effect. The present invention relates to a composition for promoting immunity induction containing at least one nuclear receptor ligand and also relates to a vaccine pharmaceutical composition for inducing immunity containing an antigen and a composition for promoting immunity induction that is at least one nuclear receptor ligand.